Zonisamide

Generic Name: Zonisamide

Brand Names: Zonegran, Zonisade, Zonisamide Mylan

Drug Type: Small Molecule

Chemical Formula: C_₈H_₈N_₂O_₃S

CAS Number: 68291-97-4

Unique Ingredient Identifier: 459384H98V

Background: Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory...

Indication: Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions: Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence

Phase 2

Completed

Conditions: Alcohol Dependence
Post-Traumatic Stress Disorder (PTSD)

Interventions: Behavioral: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Drug: Placebo
Drug: Zonisamide

First Posted Date: 2013-05-06

Last Posted Date: 2020-03-16

Lead Sponsor: Yale University

Target Recruit Count: 24

Registration Number: NCT01847469

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Study of Zonisamide in Early Parkinson Disease

Phase 2

Withdrawn

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2013-01-11

Last Posted Date: 2022-04-14

Lead Sponsor: Mazandaran University of Medical Sciences

Registration Number: NCT01766128

Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients

Phase 2

Completed

Conditions: Obesity
Obstructive Sleep Apnea
Sleep Apnea

Interventions: Drug: Placebo
Device: nCPAP
Drug: Zonisamide

First Posted Date: 2013-01-10

Last Posted Date: 2014-02-20

Lead Sponsor: Göteborg University

Target Recruit Count: 50

Registration Number: NCT01765608

Locations: 🇸🇪
Center for Sleep and Vigilance Disorders, Gothenburg, Västra Götaland, Sweden

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

Phase 1

Completed

Conditions: Nicotine Dependence

Interventions: Drug: placebo
Drug: zonisamide

First Posted Date: 2012-09-17

Last Posted Date: 2018-01-24

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 74

Registration Number: NCT01685996

Locations: 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed

Conditions: Epilepsy

Interventions: Drug: retigabine/ezogabine
Drug: lacosamide
Drug: zonisamide
Drug: pregabalin
Drug: eslicarbazepine

First Posted Date: 2012-04-30

Last Posted Date: 2013-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6498

Registration Number: NCT01587339

Zonisamide for Heavy Drinkers With Bipolar Disorder

Phase 2

Terminated

Conditions: Alcohol Use Disorders
Bipolar Disorder

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2012-03-29

Last Posted Date: 2017-01-13

Lead Sponsor: Yale University

Target Recruit Count: 3

Registration Number: NCT01566370

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.

Completed

Conditions: Partial, Generalized and Combined Seizures

Interventions: Drug: zonisamide

First Posted Date: 2011-01-25

Last Posted Date: 2014-01-27

Lead Sponsor: Eisai Inc.

Target Recruit Count: 655

Registration Number: NCT01283256

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zonegran
Drug: Zonisamide

First Posted Date: 2010-07-14

Last Posted Date: 2010-07-14

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 26

Registration Number: NCT01161966

Locations: 🇺🇸
SFBC Ft. Myers, Inc., Fort Myers, Florida, United States

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zonisamide
Drug: Zonegran

First Posted Date: 2010-07-14

Last Posted Date: 2010-07-14

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 26

Registration Number: NCT01161979

Locations: 🇺🇸
SFBC Ft. Myers, Inc., Fort Myers, Florida, United States

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: zonisamide

First Posted Date: 2010-06-10

Last Posted Date: 2022-01-04

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 121

Registration Number: NCT01140867

Locations: 🇰🇷
Kangdong Sacred Heart Hosp., Dept. of Neurology, Seoul, Korea, Republic of
🇰🇷
Bundang CHA Hospital, Dept. of Neurology, Seongnam, Korea, Republic of
🇰🇷
Dong-A University Hospital, Dept. of Neurology, Busan, Korea, Republic of

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy